AV 1142742

Drug Profile

AV 1142742

Alternative Names: AV1142742; RhuDex

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; MediGene Ltd
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action B cell inhibitors; CD80 antigen inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 13 Oct 2015 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in United Kingdom (PO)
  • 13 Oct 2015 Discontinued - Phase-II for Rheumatoid arthritis in United Kingdom (PO)
  • 13 Aug 2015 No recent reports on development identified - Phase-I for Autoimmune disorders (In volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top